vendredi 10 janvier 2020

Onco Actu du 10 janvier 2020


1. BIOLOGIE



Scientists Capture Revealing Images of Molecular Cancer Switch [Dana-Farber Cancer Institute]











2. ETIOLOGIE



Virus used in gene therapies may pose cancer risk, dog study hints Science]










2.13 ETIOLOGIE - NDMA



Mylan recalls common antacid after detecting carcinogen [Biopharma Dive]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Vaping Kills a 15-Year-Old in Texas [NY Times]











3.7 PRÉVENTION - ALCOOL



Researchers surprised by high levels of alcohol consumption among cancer survivors [EurekAlert!]











4.10 DÉP., DIAG. & PRONO. - POUMON



NHS lung cancer screening 'could save 5,000 lives a year' [The Guardian]










5.10 TRAITEMENTS - ESSAIS



The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine [Cell]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Innate Pharma provides update from regulatory agencies on lacutamab TELLOMAK trial [Innate Pharma]











Innate Pharma lacutamab trial undermined by issues with CMO [Fierce Pharma]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Aduro CEO Stephen Isaacs reaches for the budget ax — again — on the heels of their latest setback with Novartis [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Merck's Keytruda wins another first — this time for an FDA nod to treat a subset of bladder cancer patients [EndPoints]











5.16 TRAITEMENTS - CHIRURGIE



Surgery May Add Months or Years of Survival For Adults With Rare And Deadly Brain Cancers [Johns Hopkins]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Penn Medicine Shows Giving Entire Course of Radiation Treatment in Less Than a Second is Feasible [Penn Medicine]










5.2.1 PHARMA - PARTENARIATS



Pfizer taps Effector to develop anti-cancer eIF4E inhibitors [Fierce Biotech]











Pfizer taps Effector Therapeutics for its anticancer translation inhibitor [C&EN]











Eyeing the 'translatome,' Pfizer dishes out $15M for preclinical, next-gen targeted therapies [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Blueprint scores first FDA OK for a precision GIST cancer drug, just ahead of a rival treatment. And the price is a big surprise [EndPoints]










Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor [Blueprint Medicines]











FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month [Reuters]











FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation [FDA]











6. LUTTE CONTRE LES CANCERS



Experts Forecast Cancer Research and Treatment Advances in 2020 [Cancer Research Catalyst]










6.1 OBSERVATION



Colorectal cancer risk remains despite modern treatment for ulcerative colitis [Karolinska Insttitutet]











Do dietary supplements affect the survival of cancer patients? [Science-Based Medicine]